Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Enbrel 25 mg solution for injection in pre-filled syringe, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Enbrel 10 mg powder and solvent for solution for injection for paediatric use, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempi
The George Institute
juvenile idiopathic arthritis
1 trial -
Rivaroxaban 2.5 Mg Oral Tablet
The George Institute
Chronic Kidney Diseases
1 trial -
Ropivacaína Altan 2 mg/ml solución inyectable EFG, Adrenalina B. Braun 1 mg/ml Solución Inyectable
The George Institute
lumbar arthrodesis
1 trial -
SEVOFLURANE, DEXMEDETOMIDINE HYDROCHLORIDE
The George Institute
Children under the age of 2 years having surgery lasting at least 2 hours
1 trial -
STAMARIL® , poeder en oplosmiddel voor suspensie voor injectie in voorgevulde spuit. Gelekoortsvaccin (levend)., STAMARIL® , poeder en oplosmiddel voor suspensie voor injectie in voorgevulde spuit. Gelekoortsvaccin (levend)., STAMARIL® , poeder en oplosmiddel voor suspensie voor injectie in voorgevulde spuit. Gelekoortsvaccin (levend).
The George Institute
Yellow fever
1 trial -
Sevoflurano Baxter 100% líquido para inhalación del vapor EFG, Propofol Fresenius 20 mg/ml emulsión inyectable y para perfusión EFG
The George Institute
Acute ischemic stroke
1 trial -
Simvastatina NORMON 10 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 20 mg comprimidos recubiertos con película EFG, Simvastatina NORMON 40 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 40 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 10 mg comprimidos recubiertos con película EFG, Atorvastatina Normon 60 mg comprimidos recubiertos con película, Simvastatina NORMON 20 mg comprimidos recubiertos con película EFG
The George Institute
Spontaneous lobar ICH
1 trial -
Skilarence 120 mg gastro-resistant tablets, MAGNESIUM STEARATE, MICROCRYSTALLINE CELLULOSE
The George Institute
Adrenomyeloneuropathy
1 trial -
Suspension of autologous mononuclear cells separated from bone marrow aspirate
The George Institute
diabetic foot syndrome, lower limb ischemia
1 trial -
TRIGON DEPOT 40 mg/ml suspensión inyectable.
The George Institute
Chronic shoulder pain
1 trial -
TROMALYT 150 mg cápsulas duras de liberación prolongada
The George Institute
Women infertility
1 trial -
Tamoxifen Viatris 20 mg tabletter.
The George Institute
Breast Cancer
1 trial -
Testosterone Gel 1%, Decapeptyl diario 0,1 mg polvo y disolvente para solución inyectable, Astarté 0,25 mg/0,5 ml solución inyectable en jeringa precargada EFG, Bemfola 300 IU/0.50 mL solution for injection in pre-filled pen, Bomba de gel transparente, donde la sustancia activa (testosterona) fue sustituida por agua purificada.
The George Institute
low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism
1 trial -
The placebo tablet composition is: Collodial silicone dioxide, Magnesium stearate, Carmellose sodium, Cellulosa powder. Appearance and size will be the same for active and placebo., Trombyl 160 mg tabletter
The George Institute
Colon and rectal cancer tumor stage II-III, tumor with somatic alterationsin PIK3CA, PIK3R1 or PTEN
1 trial -
Tibsovo 250 mg film-coated tablets
The George Institute
ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma
1 trial -
Trulicity 0.75 mg solution for injection in pre-filled pen
The George Institute
Metabolic syndrome in patients on the waiting list for kidney transplantation, Metabolic syndrome in patients on the waiting list for kidney transplantation
1 trial -
Trulicity 0.75 mg solution for injection in pre-filled pen
The George Institute
Preventive treatment of post-kidney transplant diabetes
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet
The George Institute
Hypomethylating agent (HMA) naive myelodysplastic syndromes Myelodysplastic Symdrome (MDS), Myelodysplastic Symdrome (MDS)
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet, Placebo to Match AG-120 Tablet, 250 mg, is supplied as a film-coated tablet for oral administration.
The George Institute
Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets
The George Institute
Acute Myeloid Leukemia, ONCOLOGY
1 trial -
Zoladex 3,6 mg implante en jeringa precargada, Decapeptyl semestral 22,5 mg polvo y disolvente para suspensión de liberación prolongada inyectable., Eligard semestral 45 mg polvo y disolvente para solución inyectable., Bicalutamida Aristo 50 mg comprimidos recubiertos con película EFG
The George Institute
Prostate Cancer
1 trial -
innohep® 10.000 anti Xa IU/0,5mL PF.SYR. Ενέσιμο διάλυμα, innohep® 18.000 anti Xa IU/0,9mL PF.SYR. Ενέσιμο διάλυμα, innohep® 14.000 anti Xa IU/0,7mL PF.SYR. Ενέσιμο διάλυμα
The George Institute
Thromboprophylaxis in patients with advanced pancreatic cancer
1 trial -
-
The George Institute
Cytomegalovirus infection post allogeneic allogeneic HLA-identical familial PHT
1 trial -
-, CYCLOPHOSPHAMIDE, Cesnicabtagene autoleucel, PARACETAMOL, FLUDARABINE, LENALIDOMIDE, RoActemra 20 mg/mL concentrate for solution for infusion
The George Institute
Plasma cell leukaemia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources